Molekularbiologische Grundlagen und Diagnostik der Hämophilie B

H. H. Watzke

doi:10.1055/s-0038-1660361

Hämostaseologie, Table of Contents

Hamostaseologie 1994; 14(04): 176-183
DOI: 10.1055/s-0038-1660361

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Molekularbiologische Grundlagen und Diagnostik der Hämophilie B

H. H. Watzke

¹Abteilung für Hämatologie und Hämostaseologie, Klinik für Innere Medizin I, Wien

› Author Affiliations

Abstract

Zusammenfassung

Die Hämophilie B beruht auf einer verminderten plasmatischen Gerinnungsaktivität von Faktor IX. Dieser Defekt ist entweder durch eine verminderte Produktion von Faktor IX bedingt oder geht auf ein funktionell defektes oder auch instabiles Faktor-lX-Protein zurück. Aus klinischer Sicht ist die Hämophilie B eine Erkrankung mit einem unterschiedlichen Ausprägungsmuster, wobei die Schwere der durch den Faktor-IX-Defekt hervorgerufenen Blutungsneigung eng mit der Faktor-IX-Aktivität korreliert. Die genetische Basis dieser Erkrankung sind Mutationen im Faktor-IX-Gen. Bisher konnte der genetische Defekt bei mehr als 800 verschiedenen Patienten auf Genniveau geklärt werden. Das hat sehr wesentlich zu einem vertieften Verständnis der genetischen Ursachen der Hämophilie B geführt und den Einblick in die Struktur-Funktions-Beziehungen des FIX-Moleküls ermöglicht. Darüber hinaus wurde die pränatale Diagnostik der Hämophilie B und die Diagnostik ihres Carrierstatus entscheidend verbessert.

Schlüsselwörter

Hämophilie B - Faktor IX - genetische Defekte

Full Text

References

LITERATUR
1 Aggeler PM, White SG, Glendenning MB. et al. Plasma thromboplastin component (PTC) deficiency: a new diseases resembling hemophilia. Proc Soc Exp Biol Med 1952; 79: 692.
2 Anson DS, Choo KH, Rees DJG. et al. The gene structure of human antihaemophilic factor IX. EMBO J 1984; 03: 1053-60.
3 Bajaj SP. Cooperative Ca++ binding to factor IX. Effect of Ca++ on the kinetic parameters of the activation of FIX by FXIa. J Biol Chem 1982; 257: 4127.
4 Bentley AK, Rees DJG, Rizza C, Brownlee GG. Defective propeptide processing of blood coagulation factor IX caused by mutation of arginine to glutamine at position -4. Cell 1986; 45: 343.
5 Biggs R, Douglas AS, MacFarlane RG. et al. Christmas disease. Br Med J 1952; 02: 1378.
6 Boyd Y, Buckle VJ, Munro EA. Assignment of the haemophilia B (factor IX) locus to the q26-qter region of the X chromosome. Ann Hum Genet 1984; 48: 145.
7 Briet E, Bertina RM, Van Tilburg NH, Velt-kamp JJ. Haemophilia B Leyden: a sex linked hereditary disorder that improves after puberty. N Engl J Med 1982; 306: 788.
8 Briet E, Wijnands MC, Veitkamp JJ. The prophylactic treatment of haemophilia B Leyden with anabolic steroids. Ann Intern Med 1985; 103: 225.
9 Camerino G, Grzeschik HK, Jay M. Regional localization of the human X chromosome and polymorphism of the coagulation factor IX (hemophilia B locus). Proc Natl Acad Sci USA 1984; 81: 498.
10 Camerino G, Oberle I, Grayna D, Mandel JL. A new MspI restriction fragment length polymorphism in the hemophilia B locus. Hum Genet 1985; 71: 79.
11 Choo KH, Gould KG, Rees DJG, Brownlee GG. Molecular cloning of the gene for antihaemophilic factor IX. Nature 1982; 299: 178.
12 Chung KS, Madar DA. Goldsmith et al. Purification and characterization of an abnormal Factor IX (Christmas factor) molecule: factor IX Chapel Hill. J Clin Invest 1978; 62: 1078.
13 Coulondre C, Miller JH, Farabaugh PJ, Gilbert W. Molecular basis of base substitution hotspots in E. coli. Nature 1978; 274: 775.
14 Crossley M, Brownlee GG. Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B. Nature 1990; 354: 444-6.
15 Crossley M, Ludwig M, Stowell KM. et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX Promoter. Science 1992; 257: 377-9.
16 Davie EW. The blood coagulation factors: their cDNAs, genes, and expression. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds) Philadelphia: Lippincott; 1987
17 Diuguid DL, Rabiet MJ, Furie BC. Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the FIX precursor. Proc Natl Acad Sei USA 1986; 83: 5803.
18 Evans JP, Watzke HH, Roberts HR, High KA. Molecular cloning of a full length cDNA for canine factor IX. Blood 1989; 74: 207.
19 Fahner JB, Salier JP, Landa L. et al. Defective promoter structure in a human factor IX Leyden. Blood 1988; 72: 295A
20 Gianelli F, Green PM, High KA. et al. Haemophilia B: database of point mutations and deletions-fourth edition, 1993. Nucl Acid Res. 1993
21 Graham JB, Kunkel TR, Tennyson GS. The Malmö polymorphism of factor IX: establishing the genotypes by rapid analysis of DNA. Blood 1989; 73: 2104.
22 Hay CW, Robertson KA, Young SL. Use of BamHI polymorphism in the factor IX gene for the detection of hemophilia B carrier status. Blood 1986; 67: 1508.
23 Huang LH, Ke XH, Sweeney W, Tam JP. Calcium binding and putative activity of the epidermal growth factor domain of blood coagulation factor IX. Biochem Biophys Res Commun 1989; 160: 133.
24 Huang M-N, Kaspar CA, Roberts HR. et al. Molecular defect in factor IX Hilo, a hemophilia BM variant: Arg to Gin at the carboxy terminal cleavage site of the activation peptide. Blood 1989; 73: 781.
25 Kasper CK, Osterud B, Minami J. Hemophilia B: characterization of genetic variants and detection of carriers. Blood 1977; 50: 351.
26 Koeberl DD, Bottema CDK, Ketterling RP. et al. Mutations causing haemophilia B: direct estimates of underlying rates of spontaneous germline transitions, transversions, and deletions in the human gene. Am J Hum Genet 1990; 47: 202.
27 Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sei USA 1982; 79: 6461.
28 Liles DK, Lefkowitz J, Monroe DM, Roberts HR. Corresponding gamma-carboxyglutamyl (GLA) residues of factor IX and factor X have different functional..
29 Lozier JN, Monroe DM, Stanfield-Oakley S, Lin SW. et al. Factor IX New London: Substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood 1990; 75: 1097.
30 Ludwig M, Grimm T, Brackmann HH, Olek K. Parental origin of factor IX gene mutations, and their distribution in the gene. Am J Human Genet 1992; 50: 164.
31 Mandel JL, Willard HF, Nussbaum RL. Reports of the committee on the genetic constitution of the X chromosome. Cytogenet Cell Genet 1988; 49: 107.
32 Matthews BW, Sigler PB, Henderson R, Blow DM. Three dimensional structure of tosyl-alpha-chymotrypsin. Nature 1967; 214: 652-56.
33 McMullen BA, Fujikawa K, Kisiel W. The occurrence of beta-hydroxyaspartic acidin the vitamin K-dependent blood coagulation zymogens. Biochem Biophys Res Commun 1983; 115: 8.
34 Monroe DM, McCord DM, Huang MN. et al. Functional consequences of an Arg 180 to Glu mutation in factor IX Hilo. Blood 1989; 73: 1540.
35 Osterud B, Kasper CK, Lavine KK. et al. Purification and properties of an abnormal blood coagulation factor (factor IX BM): Kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor. Thromb Haemost 1981; 45: 55.
36 Pavlovsky A. Contribution to the pathogenesis of hemophilia. Blood 1947; 02: 185.
37 Picketts DJ. An A to T transversion at nicleotide -5 in the factor IX promoter disrupts a transcription factor binding site between nucleotides -1 and -15. Blood 1991; 78 (10) 710A.
38 Rabiet MJ, Jorgensen MJ, Furie B. Effect of propeptide mutations on post-translational processing of FIX-evidence that beta-hydroxylation and gamma-carboxylation are independent events. J Biol Chem 1987; 262: 4859.
39 Reitsma PH, Poort SR, Bernardi F. et al. Protein C deficiency: a database of mutations. Thromb Haemost 1993; 69: 77.
40 Salier JP, Hirosawa S, Kurachi K. Functional characterization of the 5’-regulatory region of human factor IX gene. J Biol Chem 1986; 265: 7062-8.
41 Schulman I, Smith CH. Hemorrhagic disease in an infant due to a previously undiscribed clotting factor. Blood 1952; 07: 794.
42 Scott CR, Chen SH, Schoof J, Kurachi K. Haemophilia B: population differences in RFLP frequencies useful for carrier detection. Am J Hum Genet 1987; 41: A262.
43 Soriano-Garcia M, Park CH, Tulinsly A, Skrzypczak-Jankun E. The structure of the Gla-domain of Ca++-prothrombin fragment. Biochemistry 1989; 28: 6805.
44 Straight DL, Sherrill GB, Noyes CM. Structural and functional characteristics of activated human factor IX after chemical modification of gamma-carboxyglutamic acid residues. J Biol Chem 1985; 260: 2890.
45 Suttie JW. Vitamin K-dependent carboxylase. Ann U Rev Biochem 1985; 54: 459.
46 Thompson AR, Chen SH, Smith KJ. Diagnostic role of an immunoassay-detected polymorphism of factor IX for potential carriers of hemophilia B. Blood 1988; 73: 1633.
47 Toomey JR, Stafford D, Smith K. Factor IX Albuqoerque (arginine 145 to cysteine) is cleaved slowly by factor XIa and has reduced coagulant activity. Blood 1988; 72: 312A.
48 von Heijne G. Signal sequences: the limits of variation. J Mol Biol 1985; 184: 99.
49 Walter J, Pabinger-Fasching I, Watzke HH. Six novel and three recurrent mutations in nine Austrian patients with hemophilia B. Thromb Haemost 1994; 72: 70-3.
50 Ware J, Diuguid DL, Liebmann HA. Factor IX San Dimas: substitution of glutamin for arginine -4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties. J Biol Chem 1989; 264: 11401.
51 Watzke HH, Lechner K, Roberts HR. et al. Molecular defect (Gla+14-Lys) and its functional consequences in a hereditary factor X deficiency (Factor X »Vorarlberg«). J Biol Chem 1990; 265: 11982.
52 Watzke HH, Walter J. Unpublizierte Beobachtung..
53 Watzke HH, Wallmark A, Hamagichi N. et al. Factor X »Santo Domingo« evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88: 1685.
54 Winship PR, Anson DS, Rizza CR, Brownlee GG. Carrier detection in hemophilia B using two further intragenic restriction fragment length polymorphisms. Nuclei Acid Res 1984; 12: 8861.
55 Wittmann E, Walter J, Pabinger-Fasching I, Watzke HH. Symptomatic hereditary type-II protein C deficiency caused by a missense mutation in exon IX of the protein C gene (Gly 381 to Ser). Ann Hematol 1994; 68: 255.
56 Yoshitake S, Schach BG, Foster DC. et al. Nucleotide sequence of the gene for human factor IX (antihemophilioc factor IX). Biochemistry 1985; 24: 3736-50.